fraxinellone has been researched along with transforming growth factor beta in 2 studies
| Studies (fraxinellone) | Trials (fraxinellone) | Recent Studies (post-2010) (fraxinellone) | Studies (transforming growth factor beta) | Trials (transforming growth factor beta) | Recent Studies (post-2010) (transforming growth factor beta) |
|---|---|---|---|---|---|
| 46 | 0 | 34 | 49,119 | 560 | 17,610 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gu, L; Ma, Y; Shao, F; Sun, B; Sun, Y; Tan, T; Tan, Y; Wu, X; Xu, Q; Zhou, Y | 1 |
| Chen, J; Chen, L; Chen, Y; Feng, J; Gao, X; Gu, X; Huang, Y; Jiang, G; Pei, Y; Song, Q; Wang, J; Xu, M; Zhang, Q | 1 |
2 other study(ies) available for fraxinellone and transforming growth factor beta
| Article | Year |
|---|---|
CUG-binding protein 1 regulates HSC activation and liver fibrogenesis.
Topics: 3' Untranslated Regions; Animals; Benzofurans; CELF1 Protein; Cells, Cultured; Gene Expression Regulation; Hepatocytes; Humans; Interferon-gamma; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; p38 Mitogen-Activated Protein Kinases; Protein Binding; RNA Interference; RNA, Messenger; Transforming Growth Factor beta | 2016 |
Sequential Targeting TGF-β Signaling and KRAS Mutation Increases Therapeutic Efficacy in Pancreatic Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apolipoprotein E3; Benzofurans; Drug Administration Schedule; Drug Carriers; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Molecular Targeted Therapy; Mutation; Nanoparticles; NIH 3T3 Cells; Pancreatic Neoplasms; Peptide Fragments; Proto-Oncogene Proteins p21(ras); RNA, Small Interfering; Signal Transduction; Transforming Growth Factor beta; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |